|Videos|April 20, 2022
Safety and Efficacy Data: The CheckMate 214 Trial
Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.
Advertisement
Episodes in this series
Advertisement
Related to this article
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
3
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
4
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
5